Feedback
  • Article / Essay
  • Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors…

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II

Affiliation
Department of Breast Surgical Oncology ,National Cancer Center ,National Clinical Research Center for Cance ,Cancer Hospital ,Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing ,China
Lei, Chuqi;
Affiliation
Department of Breast Surgical Oncology ,National Cancer Center ,National Clinical Research Center for Cance ,Cancer Hospital ,Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing ,China
Kong, Xiangyi;
Affiliation
Center for Melanoma ,Massachusetts General Hospital Cancer Center ,Harvard Medical School ,Harvard University ,Boston ,MA ,United States
Sullivan, Ryan J.;
Affiliation
Laboratory Animal Center ,Xiamen University ,Xiamen ,China
Wu, Caisheng;
Affiliation
Department of Urology ,Ruijin Hospital ,School of Medicine ,Shanghai Jiaotong University ,Shanghai ,China
Wang, Dawei;
Affiliation
Institute of Artificial Intelligence ,Hefei Comprehensive National Science Center ,Hefei ,China
Zhang, Lin

Preview

Category

Published in:
Frontiers in Pharmacology
Vol. 14 (06.02.2023)
Volume:
14
Date Issued:
06.02.2023
DOI:
10.3389/fphar.2023.1136373
Language:
English
Type of Resource:
Text
Keywords:
PD-1/PD-L1 inhibitors; toxicity mechanism; clinical features; immunotherapy; cancer
DDC subject of DNB:
610 Medical sciences Medicine

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:
open graphic

Rights

License Holder: Copyright © 2023 Lei, Kong, Sullivan, Wu, Wang and Zhang.

Use and reproduction: